White Paper

Flexible Platform Solutions Overcome Vaccine Production Challenges

Packaging vaccine syringe world

Vaccines have been used since Edward Jenner first experimented with smallpox in the 1790s and have evolved significantly in modern times. Today, vaccines have a diversity of antigens and targets, and with advances in drug manufacturing there is a huge variety of development and administration formats.

The team from Pall Biotech explores the challenges of vaccine development and how they can be overcome by applying a quality by design (QbD) platform approach from early process development phases forward. The impact of the COVID-19 pandemic on vaccine production is evaluated, with insight on how flexible, integrated, closed-system processing is advancing the future of safe and efficacious vaccine production.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online